170 related articles for article (PubMed ID: 37701337)
41. Case Report: A rare case of young adult progressive familial intrahepatic cholestasis-type 3 with a novel heterozygous pathogenic variant of
Zhu H; Wang S; Li L; Geng W; Wan X; Hua R; Wang D; Gao P
Front Pediatr; 2022; 10():1012825. PubMed ID: 36330364
[TBL] [Abstract][Full Text] [Related]
42. Functional characterization of ABCB4 mutations found in progressive familial intrahepatic cholestasis type 3.
Park HJ; Kim TH; Kim SW; Noh SH; Cho KJ; Choi C; Kwon EY; Choi YJ; Gee HY; Choi JH
Sci Rep; 2016 Jun; 6():26872. PubMed ID: 27256251
[TBL] [Abstract][Full Text] [Related]
43. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver.
Parés A; Caballería L; Rodés J; Bruguera M; Rodrigo L; García-Plaza A; Berenguer J; Rodríguez-Martínez D; Mercader J; Velicia R
J Hepatol; 2000 Apr; 32(4):561-6. PubMed ID: 10782903
[TBL] [Abstract][Full Text] [Related]
44. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
45. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
Corpechot C; Chazouillères O; Belnou P; Montano-Loza AJ; Mason A; Ebadi M; Eurich D; Chopra S; Jacob D; Schramm C; Sterneck M; Bruns T; Reuken P; Rauchfuss F; Roccarina D; Thorburn D; Gerussi A; Trivedi P; Hirschfield G; McDowell P; Nevens F; Boillot O; Bosch A; Giostra E; Conti F; Poupon R; Parés A; Reig A; Donato MF; Malinverno F; Floreani A; Russo FP; Cazzagon N; Verhelst X; Goet J; Harms M; van Buuren H; Hansen B; Carrat F; Dumortier J;
J Hepatol; 2020 Sep; 73(3):559-565. PubMed ID: 32275981
[TBL] [Abstract][Full Text] [Related]
46. Molecular basis of progressive familial intrahepatic cholestasis 3. A proteomics study.
Guerrero L; Carmona-Rodríguez L; Santos FM; Ciordia S; Stark L; Hierro L; Pérez-Montero P; Vicent D; Corrales FJ
Biofactors; 2024 Jan; ():. PubMed ID: 38284625
[TBL] [Abstract][Full Text] [Related]
47. Clinical Outcomes and Validation of Ursodeoxycholic Acid Response Scores in Patients with Korean Primary Biliary Cholangitis: A Multicenter Cohort Study.
Chang JI; Kim JH; Sinn DH; Cho JY; Kim KM; Oh JH; Park Y; Sohn W; Goh MJ; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Gut Liver; 2023 Jul; 17(4):620-628. PubMed ID: 36999383
[TBL] [Abstract][Full Text] [Related]
48. Identification of a primary biliary cirrhosis associated protein as lysosome-associated membrane protein-2.
Wang L; Wang J; Shi Y; Zhou X; Wang X; Li Z; Huang X; Wang J; Han Z; Li T; Wang M; Wang R; Fan D; Han Y
J Proteomics; 2013 Oct; 91():569-79. PubMed ID: 24007661
[TBL] [Abstract][Full Text] [Related]
49. Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid.
Parés A
Dig Dis; 2015; 33 Suppl 2():125-33. PubMed ID: 26642350
[TBL] [Abstract][Full Text] [Related]
50. Progressive Familial Intrahepatic Cholestasis (PFIC) in Indian Children: Clinical Spectrum and Outcome.
Agarwal S; Lal BB; Rawat D; Rastogi A; Bharathy KG; Alam S
J Clin Exp Hepatol; 2016 Sep; 6(3):203-208. PubMed ID: 27746616
[TBL] [Abstract][Full Text] [Related]
51. Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis.
Heathcote EJ; Stone J; Cauch-Dudek K; Poupon R; Chazouilleres O; Lindor KD; Petz J; Dickson ER; Poupon RE
Liver Transpl Surg; 1999 Jul; 5(4):269-74. PubMed ID: 10388499
[TBL] [Abstract][Full Text] [Related]
52. Combined features of low phospholipid-associated cholelithiasis and progressive familial intrahepatic cholestasis 3.
Poupon R; Barbu V; Chamouard P; Wendum D; Rosmorduc O; Housset C
Liver Int; 2010 Feb; 30(2):327-31. PubMed ID: 19840255
[TBL] [Abstract][Full Text] [Related]
53. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
Trauner M; Fickert P; Halilbasic E; Moustafa T
Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
[TBL] [Abstract][Full Text] [Related]
54. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
[TBL] [Abstract][Full Text] [Related]
55. Presentation of Progressive Familial Intrahepatic Cholestasis Type 3 Mimicking Wilson Disease: Molecular Genetic Diagnosis and Response to Treatment.
Boga S; Jain D; Schilsky ML
Pediatr Gastroenterol Hepatol Nutr; 2015 Sep; 18(3):202-8. PubMed ID: 26473142
[TBL] [Abstract][Full Text] [Related]
56. Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to 28 Years.
Chang ML; Chen WT; Chan TM; Lin CY; Chang MY; Chen SC; Chien RN
Front Immunol; 2022; 13():869018. PubMed ID: 35663951
[TBL] [Abstract][Full Text] [Related]
57. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
Paumgartner G; Beuers U
Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
[TBL] [Abstract][Full Text] [Related]
58. Liver pathology in severe multidrug resistant 3 protein deficiency: a series of 10 pediatric cases.
Vij M; Safwan M; Shanmugam NP; Rela M
Ann Diagn Pathol; 2015 Oct; 19(5):277-82. PubMed ID: 26117383
[TBL] [Abstract][Full Text] [Related]
59. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
[TBL] [Abstract][Full Text] [Related]
60. Use of ursodeoxycholic acid in patients with liver disease.
Angulo P
Curr Gastroenterol Rep; 2002 Feb; 4(1):37-44. PubMed ID: 11825540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
